KRYS - Krystal Biotech, Inc.

276.5
2.290   0.828%

Share volume: 210,387
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$274.21
2.29
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 15%
Dept financing 3%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.71%
1 Month
10.56%
3 Months
-3.32%
6 Months
44.93%
1 Year
70.77%
2 Year
75.83%
Key data
Stock price
$276.50
P/E Ratio 
34.90
DAY RANGE
$272.00 - $278.86
EPS 
$7.08
52 WEEK RANGE
$122.80 - $298.30
52 WEEK CHANGE
$63.80
MARKET CAP 
7.149 B
YIELD 
N/A
SHARES OUTSTANDING 
29.232 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-04-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$273,098
AVERAGE 30 VOLUME 
$272,101
Company detail
CEO: Krish S. Krishnan
Region: US
Website: krystalbio.com
Employees: 210
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.

Recent news